Ikashi Screener(USA)

JOHNSON & JOHNSON

JNJ · CIK 0000200406 · NYSE · Healthcare (Pharmaceutical Preparations)

Overview — JOHNSON & JOHNSON

Revenue (TTM)
$99.33B
Net Income (TTM)
$16.09B
Total Assets
$197.43B
Total Debt
$35.80B

Pros

  • Strong free cash flow generation
  • Operating cash flow comfortably exceeds reported net income

Cons

    Chart

    182206230254278Volume

    Revenue & Net Income

    RevenueNet Income
    025B50B75B100B201720182019202320242025TTM

    Peers

    Sector: Healthcare. Sector is derived from SEC's SIC code, not GICS. Click a column to sort.

    CompanyMarket Cap ▼Revenue (TTM) Net Income (TTM) Net Margin ROE Debt/Equity
    JNJ JOHNSON & JOHNSON$660.42B$99.33B$16.09B16.2%19.7%0.44
    PFE PFIZER INC$169.02B$63.70B$4.36B6.8%5.1%0.71
    ABBV AbbVie Inc.—$64.39B$6.32B9.8%-106.4%—
    MRK Merck & Co., Inc.—$66.57B$3.17B4.8%7.6%1.28
    MMM 3M CO—$25.25B$3.58B14.2%85.9%3.01

    Quarterly results

    Line itemJul 23Oct 23Dec 23Mar 24Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26Sep 26
    Revenue$25.53B$21.35B$21.39B$21.38B$22.45B$22.47B$21.89B$23.74B$23.99B$24.06B$25.31B$25.40B
    Net Income$5.14B$26.03B$4.05B$3.25B$4.69B$2.69B$11.00B$5.54B$5.15B$5.24B$5.53B$210.00M
    Operating Cash Flow———$3.66B——$4.17B——$2.51B——

    Profit & Loss

    Line item201720182019202320242025TTM
    Revenue$76.45B$81.58B$82.06B$85.16B$88.82B$94.19B$99.33B
    Net Income$1.30B$15.30B$15.12B$35.15B$14.07B$26.80B$16.09B

    Balance Sheet

    Line item201720182019202320242025TTM
    Total Assets————$180.10B$199.21B$197.43B
    Total Liabilities————$108.61B$117.67B$115.90B
    Total Equity————$71.49B$81.54B$81.53B
    Total Debt————$30.65B$39.44B$35.80B
    Shares Outstanding————2,407,616,6932,409,898,9362,407,310,266

    Cash Flow

    Line item201720182019202320242025TTM
    Operating Cash Flow$21.06B$22.20B$23.42B$22.79B$24.27B$24.53B$22.87B
    Capex$3.28B$3.67B$3.50B$4.54B$4.42B$4.83B$5.09B

    Ratios

    Profitability

    Ratio201720182019202320242025TTM
    Net margin1.7%18.8%18.4%41.3%15.8%28.5%16.2%
    Return on equity————19.7%32.9%19.7%
    Return on assets————7.8%13.5%8.2%
    Return on capital employed (ROCE)———————
    Debt / Equity————0.430.480.44
    FCF margin23.3%22.7%24.3%21.4%22.3%20.9%17.9%

    Working capital

    Ratio201720182019202320242025TTM
    Debtor days————61d67d70d
    Inventory days————165d171d174d
    Payable days————137d145d106d
    Cash conversion cycle————89d93d138d
    Working capital days————23d6d3d

    Investors

    US filings have no equivalent to India's Promoter/FII/DII shareholding-pattern disclosure. Shown below are the closest real US sources: Form 4 insider transactions and Form 13F institutional holders (matched by issuer name, not CUSIP — a few companies, especially ones that changed their legal name, may be incomplete).

    Institutional Holders

    No data yet — run npm run ingest:institutions in apps/api.

    Insider Trades

    PersonRelationshipDateTypeSharesPrice
    Schmid TimothyEVP, WW Chair, MedTech9/2/2026Option exercise11,070$131.94
    Schmid TimothyEVP, WW Chair, MedTech9/2/2026Sale11,070$274.74
    Schmid TimothyEVP, WW Chair, MedTech9/2/2026Option exercise22,527$151.41
    Schmid TimothyEVP, WW Chair, MedTech9/2/2026Sale22,527$274.74
    Taubert Jennifer LEVP, WWC. Innovative Medicine8/17/2026Option exercise15,000$115.67
    Taubert Jennifer LEVP, WWC. Innovative Medicine8/17/2026Sale15,000$263.36
    Duato JoaquinCEO and Chairman of the Board8/13/2026Option exercise123,291$115.67
    Duato JoaquinCEO and Chairman of the Board8/13/2026Sale20,976$262.00
    Duato JoaquinCEO and Chairman of the Board8/13/2026Sale102,315$261.00
    Forminard ElizabethEVP, Chief Legal Officer8/6/2026Option exercise9,344$131.94
    Forminard ElizabethEVP, Chief Legal Officer8/6/2026Sale9,344$257.75
    Forminard ElizabethEVP, Chief Legal Officer8/6/2026Sale6,574$255.93
    Duato JoaquinCEO and Chairman of the Board8/5/2026Sale41,957$258.06
    Duato JoaquinCEO and Chairman of the Board8/5/2026Sale6,523$258.74
    Broadhurst VanessaEVP, Global Corp Affairs7/20/2026Option exercise11,129$129.51
    Broadhurst VanessaEVP, Global Corp Affairs7/20/2026Option exercise11,925$131.94
    Broadhurst VanessaEVP, Global Corp Affairs7/20/2026Sale23,054$251.27
    Wengel Kathryn EEVP, Chief TO and Risk Officer6/11/2026Option exercise10,000$115.67
    Wengel Kathryn EEVP, Chief TO and Risk Officer6/11/2026Sale10,000$241.15
    REED JOHN CEVP, Innovative Medicine, R&D5/1/2026Option exercise25,255—
    REED JOHN CEVP, Innovative Medicine, R&D5/1/2026Tax withholding11,002$229.85

    Documents